Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.
Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.
Notable practitioner
Life Sciences and Healthcare - "Stand out partner for me has been Colin McCall, who has single-handedly helped us get a hugely complex licensing deal over the line. His understanding of the detail of licence terms and the complex background to the development of the IP was instrumental to making all the parties make appropriate concessions to getting a deal over the line, and avoiding lengthy stand offs and threats of walking away."
Biotechnology: "Colin McCall has provided excellent service – he makes sure to understand the client’s needs and reliably delivers high-quality work within the agreed timelines and budgets. He is an excellent communicator, very personable and a pleasure to deal with."
Intellectual Property
IP - contentious and non-contentious
We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.
Press releaseIncluding on its transformational licensing and equity investment deals done with Weichai Power in China and with Robert Bosch GmbH in respect of Ceres Power's solid oxide fuel cell technology.
Advised Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.
Press releaseOxford BioMedica on various commercial and licensing deals including its collaboration, development and licence agreement with Novartis in respect of Kymriah, which became the first gene therapy ever to receive FDA approval and on its manufacturing agreements for clinical and commercial supply of Kymriah to Novartis.
Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.
Shire Pharmaceuticals on its review and subsequent improvement of its contractual arrangements for distribution and supply of its global portfolio of products in order to make Shire acquisition ready.
作者 Colin McCall 以及 Charlie Adams
Taylor Wessing advises Cumulus Oncology on its exclusive GPR68 licence and development collaboration with leadXpro
作者
作者
作者
作者
作者 Alison Dennis 以及 Alice Matthews
作者
作者 Michael Goldberg 以及 Leona Ahmed
作者